Exhibit 10.78

 

 

Exchange & Venture Agreement

by and among

Cardiotech International, Inc.,

Implant Sciences, Inc.

and

CorNova, Inc.

 

 

March 5, 2004

 

--------------------------------------------------------------------------------

 

 

 

EXCHANGE & VENTURE AGREEMENT

 

 

This EXCHANGE & VENTURE AGREEMENT dated March 5, 2004 (“Agreement”) by and among
Cardiotech International, Inc. (“Cardiotech”), a Delaware corporation with its
principal executive offices at 78E Olympia Avenue, Woburn, Massachusetts 01801,
(AMEX: CTE), and Implant Sciences, Inc. (“Implant”), a Delaware corporation with
its principal executive offices at 107 Audubon Road #5, Wakefield, Massachusetts
01880, (AMEX: IMX); (Cardiotech and Implant are collectively referred to herein
as the “Participants “), and CorNova, Inc., a Delaware corporation with its
principal executive offices at 274 Ash Street, Hopkinton, Massachusetts 01748
(the “Company” or “CorNova”).

 

R E C I T A L S :

 

FINANCING AND SHARE EXCHANGE

 

WHEREAS, the Participants wish to contribute certain of their shares to the
Company in exchange for shares of the Company in accordance with the terms and
conditions hereinafter set forth.

 

WHEREAS, the Participants will issue shares of their common stock bearing an
aggregate fair market value of one hundred fifty thousand dollars ($150,000)
valued at the end of business on November 18, 2003 to CorNova as follows: 
Cardiotech will issue 12,931 shares, and Implant will issue 10,344 shares (the
12,931 and 10,344 shares shall be referred to collectively as the “Contributory
Shares”).

 

WHEREAS, CorNova, upon receipt of the Contributory Shares, shall simultaneously
issue and deliver one million five hundred thousand (1,500,000) shares of its
common stock to each of Cardiotech and Implant, such shares constituting sixty
percent (60%) of CorNova’s issued and outstanding shares, on a fully diluted
basis, as of the date of issuance.

 

WHEREAS, CorNova will use its best efforts to borrow a minimum of fifty thousand
dollars ($50,000) and up to one hundred fifty thousand dollars ($150,000) in
seed capital in 2004 to finance the startup of its operations (“Seed Loans”).

 

WHEREAS, CorNova intends to raise a minimum of one million dollars ($1,000,000)
and up to three million dollars ($3,000,000) in a Series A financing round to
close in 2004 (“Series A Financing”).

 

WHEREAS, upon the closing of the minimum Series A Financing, the Participants
will each issue shares of their common stock equal to up to twenty-five percent
(25%) of the gross amount of the Series A Financing up to the maximum of three

 

--------------------------------------------------------------------------------

 

Cornova, Inc.
Exchange & Venture Agreement

 

million dollars ($3,000,000) (the “Investment Shares”); bearing an aggregate
fair market value of up to one million five hundred thousand dollars
($1,500,000) valued at the end of business on the day immediately preceding the
date of the Series A Financing Closing.

 

 

TECHNOLOGY & VENTURE

 

WHEREAS, CorNova is a start-up company, which has not incurred any debts or
liabilities in excess of fifty thousand dollars ($50,000) in the aggregate,
focused on the development and marketing of innovative interventional cardiology
products.  The initial target of CorNova is the development of a next-generation
drug-eluting stent.

 

WHEREAS, CorNova possesses, will develop or will acquire the intellectual
property relating to stent design, CE testing and drug coatings.

 

WHEREAS, Cardiotech intends to grant to CorNova an exclusive license for the
technology consisting of Chronoflex DES polymer or any poly (carbonate) urethane
and containing derivative thereof solely for use on drug-eluting stents.

 

WHEREAS, Utilizing the combined capabilities of the Participants, CorNova will
seek to produce a novel coronary stent system whose design, materials, and
manufacturing will be specific for drug elution technology.

 

NOW THEREFORE, in consideration of one dollar and the exchange of shares to be
made, the mutual benefits to be derived hereby and the representations,
warranties, covenants and agreements herein contained, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged, CorNova and the Participants agree as follows:

 

ARTICLE I.     Contributory Shares

 

1.1  Cardiotech Contributory Shares.

  Subject to the terms and conditions hereinafter set forth, Cardiotech shall
issue, transfer and deliver to CorNova an aggregate of twelve thousand nine
hundred thirty-one (*12,931*) shares of Cardiotech common stock, $.01 par value
(the “Cardiotech Contributory Shares”) within fifteen (15) days of the execution
of this Agreement.  Upon receipt of the Cardiotech Contributory Shares, the
Company shall simultaneously issue and deliver 1,500,000 shares of its common
stock to Cardiotech, such shares constituting thirty percent (30%) of CorNova’s
issued and outstanding shares, on a fully diluted basis, as of the date of
issuance.

 

1.2           Implant Contributory Shares.

  Subject to the terms and conditions hereinafter set forth, Implant shall
issue, transfer and

 

2

--------------------------------------------------------------------------------

 

deliver to CorNova an aggregate of ten thousand three hundred forty-forty
(*10,344*) shares of Implant common stock, $.10 par value (the “Implant
Contributory Shares”) within fifteen (15) days of the execution of this
Agreement.  Upon receipt of the Implant Contributory Shares, the Company shall
simultaneously issue and deliver 1,500,000 shares of its common stock to
Implant, such shares constituting thirty percent (30%) of CorNova’s issued and
outstanding shares, on a fully diluted basis, as of the date of issuance.

 

1.3           Terms of Contributory Shares.

  The Cardiotech Contributory Shares and the Implant Contributory Shares shall
be referred to collectively herein as the “Contributory Shares”.  The
Contributory Shares shall have the terms and be issued subject to the conditions
as set forth herein and in the respective certificates of incorporation of the
Participants as filed and recorded with the Secretary of State of the State of
Delaware.  The Contributory Shares shall be contributed to CorNova to assist in
securing the Seed Loans and to serve as collateral against such loans in
anticipation of the Participants respective anticipated participation in CorNova
and Technology.

 

ARTICLE II.     CorNova Obligations upon Contributory Shares

 

II-A. Simultaneous with receipt of the Contributory Shares by CorNova:

 

2.1           Seed Loans.  CorNova shall use its best efforts to borrow a
minimum of fifty thousand dollars ($50,000) and up to one hundred fifty thousand
dollars ($150,000) in seed capital in 2004 to finance the startup of its
operations (“Seed Loans”) under the following terms and conditions:

 

(a)          The Seed Loans shall become due and payable fifteen months from
receipt of the loan.

(b)         The Seed Loans shall bear simple interest at an annual rate of ten
percent (10%).

(c)          The Seed Loans shall be secured by the Contributory Shares, as
defined below.

(d)         The lenders making the Seed Loans shall be issued warrants in
proportion to the amount of all of the Seed Loans made.  Assuming the maximum
Seed Loans, the Seed Loan lender(s) shall receive an aggregate of one hundred
fifty thousand (150,000) warrants (“Warrants”).  The Warrants shall entitle the
holders thereof to purchase, in the aggregate, one hundred fifty thousand
(150,000) shares of common stock of CorNova on or before January 5, 2007.  The
number of Warrants shall be reduced on a dollar-for-dollar basis based on the
size of the Seed Loans. The exercise price of each of the Warrants shall be one
hundred twenty percent (120%) of the fair market value of the shares of CorNova
as of the date of the closing of the Seed Loans as determined in the reasonable
discretion of by the board of directors of CorNova.

(e)          The proceeds of the Seed Loans and the exercise of the Warrants
shall be used for start-up capital, expenses of the Series A Preferred stock
capital raise, initial monthly

 

3

--------------------------------------------------------------------------------

 

salary of the chairman of CorNova, professional fees, and general working
capital purposes.

(f)            The capitalization of CorNova shall not exceed five million
(5,000,000) shares of common stock on a fully diluted basis, including the
shares of common stock underlying the Warrants, immediately following the
issuance of the Contributory Shares.

(g)         The lenders making the Seed Loans shall qualify as accredited
investors under the Securities Laws.

(h)         Such other terms and conditions as set forth in the form
Subscription and Loan Agreements and the Shareholder-Lender Promissory Notes
evidencing the Seed Loans.

 

II-B. Upon receipt of the Contributory Shares by CorNova:

 

2.2           Board Representation.  CorNova shall, by written consent of a
majority of the shareholders of CorNova, increase the size of its board and
appoint Dr. Michael Szycher and Dr. Anthony J. Armini to be directors of CorNova
on its board of directors.  The board of directors of CorNova shall then be
entirely comprised of:  Dr. Stephen Eric Ryan, Dr. Michael Szycher and Dr.
Anthony J. Armini.

 

2.3           Chairman & CEO Compensation.  (a) Upon closing of the minimum Seed
Loans, CorNova shall provide monthly compensation to S. Eric Ryan, pursuant to
the conditions set forth in the consulting agreement attached hereto as Exhibit
2.3, for his services as CEO of CorNova at the monthly rate of eight thousand
dollars ($8,000).  CorNova shall also provide up to one thousand dollars
($1,000) per month for health insurance for S. Eric Ryan and his family upon the
closing of the minimum Seed Loans.  Upon closing of the at least the minimum
Series A Financing the consulting agreement will expire.

 

  (b) CorNova shall negotiate a separate employment agreement with S. Eric Ryan
for the continuation of his services as Chairman and CEO with a base salary of
at least fifteen thousand dollars ($15,000) per month.  CorNova shall also
provide up to $1,000 per month for health insurance for S. Eric Ryan and his
family.  Such employment agreement is to commence after expiration of the
consulting agreement and upon the closing of at least the minimum Series A
Financing.  Further, Dr. Ryan will be paid a bonus equal to one full year of his
full salary upon either (a) receipt by CorNova of the release and discharge of
the security interests which are to be filed against the Investment Shares in
favor of the Series A Investors, or (b) the occurrence of an event requiring
mandatory conversion of the then outstanding preferred stock of CorNova.

 

2.4           Series A Offering.  CorNova shall commence on a best efforts basis
its Series A Financing, as hereinafter defined, under the following terms and
conditions:

 

(a)          The Series A Financing shall commence within thirty (30) days of
the

 

4

--------------------------------------------------------------------------------

 

closing of the Seed Loans and shall be completed or terminated twelve (12)
months after such commencement date; however, CorNova shall have an additional
thirty (30) days after the completion or termination date to close on any then
outstanding subscriptions to purchase any Series A Preferred Stock.

(b)         CorNova shall amend its certificate of incorporation to provide for
a series of convertible voting preferred stock (“Series A Preferred Stock”)
which shall be the securities offered and sold in the Series A Financing.

(c)          The purchase price per share of the Series A Preferred Stock is
proposed to equal one dollar 20/100 ($1.20) (the “Series A Price”).

(d)         The Series A Preferred Stock shall not be sold for less than one
dollar ($1.00) per share without the express written agreement of the board of
directors of CorNova.

(e)          The conversion price of the Series A Preferred Stock shall be
convertible at no cost to the Series A Preferred holder (the “Conversion
Price”).  Each share of Preferred Stock shall be convertible at the option of
the holder into one (1) share of fully paid and nonassessable shares of the
common stock of CorNova.

(f)            Conversion of the Series A Preferred Stock will be mandatory upon
an initial public offering of CorNova raising in excess of ten million dollars
($10,000,000), or an acquisition for at least eighty percent (80%) of CorNova at
a minimum purchase price of two dollars 50/100 ($2.50) per share, or upon
receipt of CE mark approval of the Technology.

(g)         The Series A Financing offering shall consist of a minimum of one
million dollars ($1,000,000) and a maximum of three million dollars
($3,000,000).

(h)         CorNova does not anticipate that the holders of the Series A
Preferred Stock shall be entitled to dividend, and the designation for the
Series A Preferred Stock shall not be amended without the express written
agreement of the board of directors of CorNova.

(i)             The liquidation preference of the Series A Preferred Stock shall
be equal to the Series A Price.

(j)             The redemption rate of the Series A Preferred Stock shall not
exceed one and 50/100 ($1.50) dollars per share without the express written
agreement of the board of directors of CorNova.

(k)          The investors of the Series A Financing shall receive a senior
security interest in the Investment Shares (collectively “Series A Secured
Interest”) subject to certain terms and conditions.

(l)             The Series A Secured Interest shall be equal in all respects and
of equal parity, position and priority as among each Series A Financing
investor.

(m)       The Series A Secured Interest shall expire and be released upon
CorNova achieving either of two milestones: (i) CorNova securing a CE mark, or
such other European authority approval, of a bare coronary stent system, and/or
(ii) preclinical demonstration of a drug-eluting stent yielding results of at
least a fifty percent (50%) reduction in intimal hyperplasia.

 

II-C.

2.5           Rescission and Termination If No Minimum Seed Loans.  In the event
the

 

5

--------------------------------------------------------------------------------

 

closing of at least the minimum Seed Loans has not occurred within ninety (90)
days of the date of this Agreement, the Participants shall together have the
right to rescind and terminate this Agreement.  Upon such rescission and
termination by both Participants, the Participants shall each return for
cancellation the CorNova Shares in exchange for the Contributory Shares.  Upon
receipt by CorNova of written notice from both Participants and receipt by
CorNova of the CorNova Shares, CorNova shall immediately return and deliver: (a)
all of the Cardiotech Shares to Cardiotech, and (b) all of the Implant Shares to
Implant.  Immediately thereafter, this Agreement shall be of no force and
effect.

 

ARTICLE III.     Investment Shares

 

3.1                                 Cardiotech Investment Shares.  Upon CorNova
securing the minimum Series A Financing subject to the terms and conditions
hereinafter set forth, Cardiotech shall issue, transfer and deliver to CorNova
an amount of Cardiotech common stock, $.01 par value, (the “Cardiotech
Investment Shares”) which amount shall be calculated based upon the five (5) day
average of the fair market value of the closing price of Cardiotech common stock
as published in the Wall Street Journal on the dates immediately preceding each
relevant closing of the Series A Financing.  The amount of the Cardiotech
Investment Shares shall be equal to twenty-five percent (25%) of the gross
dollar amount of the Series A Financing raised and invested in CorNova on a pro
rata basis up to the maximum Series A Financing amount.  Thus, Cardiotech will
be obligated to issue and deliver to CorNova the Cardiotech Investment Shares
equal to two hundred fifty thousand dollars ($250,000) in value if the minimum
Series A Financing is completed; and Cardiotech will be obligated to issue and
deliver to CorNova the Cardiotech Investment Shares equal to seven hundred fifty
thousand dollars ($750,000) in value if the maximum Series A Financing is
completed.  In the event the Series A Financing exceeds its maximum of three
million dollars ($3,000,000), Cardiotech shall be obligated to only contribute
Cardiotech Investment Shares equal to seven hundred fifty thousand dollars
($750,000) in value.

 

3.2                                 Implant Investment Shares.  Upon CorNova
securing the minimum Series A Financing subject to the terms and conditions
hereinafter set forth, Implant shall issue, transfer and deliver to CorNova an
amount of Implant common stock, $.10 par value, (the “Implant Investment
Shares”) which amount shall be calculated based upon the five (5) day average of
the fair market value of the closing price of Implant common stock as published
in the Wall Street Journal on the dates immediately preceding each relevant
closing of the Series A Financing.  The amount of the Implant Investment Shares
shall be equal to twenty-five percent (25%) of the gross dollar amount of the
Series A Financing raised and invested in CorNova on a pro rata basis up to the
maximum Series A Financing amount.  Thus, Implant will be obligated to issue and
deliver to CorNova the Implant Investment Shares equal to two hundred fifty
thousand dollars ($250,000) in value if the minimum Series A Financing is
completed; and Implant will be obligated to issue and deliver to CorNova the
Implant Investment Shares equal to seven hundred fifty thousand dollars
($750,000) in value if the maximum Series A Financing is completed.  In the
event

 

6

--------------------------------------------------------------------------------

 

the Series A Financing exceeds its maximum of three million dollars
($3,000,000), Implant shall be obligated to only contribute Implant Investment
Shares equal to seven hundred fifty thousand dollars ($750,000) in value.

 

3.3           Investment Shares.  The Cardiotech Investment Shares and the
Implant Investment Shares shall be referred to collectively herein as the
“Investment Shares”.  The Investment Shares shall be issued subject to the
conditions as set forth herein and in the respective certificates of
incorporation of the Participants as filed and recorded with the Secretary of
State of the State of Massachusetts.

 

3.4           Subsequent Tranches of Investment Shares.  (a)  The offering of
the Series A Financing may be continued until the maximum amount of capital has
been raised, but no later than February 28, 2005.  At each subsequent closing
tranche, the Participants shall be obligated to issue Investment Shares as
provided for under this Article III to maintain its twenty-five percent (25%)
pro rata portion of the Investment Shares to be issued.

 

  (b)  Upon CorNova securing additional Series A Financing up to the maximum
three million dollars ($3,000,000), each Participant shall issue, transfer and
deliver to CorNova its pro rata amount of its Investment Shares which amount
shall be calculated as set forth above.  The amount of additional Investment
Shares from each Participant to be issued at each subsequent closing tranche
shall be that pro rata number of new shares separately combined with all
previous issuances of Investment Shares from each Participant which shall equal
twenty-five percent (25%) [fifty percent (50%) in the aggregate] of the gross
dollar amount of the Series A Financing raised and invested in CorNova up to
twenty-five percent (25%) [fifty percent (50%) in the aggregate] of the maximum
Series A Financing amount.

 

  (c)  CorNova, at its option and in its sole discretion, may delay the closing
of the minimum Series A Financing, and each subsequent tranche closing, in order
to sell and close on a greater number Series A shares in each tranche; provided
that each closing occur no later than twelve (12) months from the date of the
closing of the minimum Seed Loans, plus 30 days for subscriptions then existing
but not then closed.

 

ARTICLE IV.     CorNova Shares

 

4.1                                 CorNova Shares to Cardiotech.  Upon receipt
by CorNova of the Contributory Shares, CorNova shall simultaneously issue, and
deliver to Cardiotech one million five hundred thousand (*1,500,000*) shares of
the common stock of CorNova, par value $.0001 per share, representing thirty
percent (30%) of the issued and outstanding capital stock of CorNova immediately
prior to the issuance of any shares under the Series A Financing.

 

4.2                                 CorNova Shares to Implant.  Upon receipt by
CorNova of the Contributory

 

7

--------------------------------------------------------------------------------

 

Shares, CorNova shall simultaneously issue, and deliver to Implant one million
five hundred thousand (*1,500,000*) shares of the common stock of CorNova, par
value $.0001 per share, representing thirty percent (30%) of the issued and
outstanding capital stock of CorNova immediately prior to the issuance of any
shares under the Series A Financing.

 

4.3                                 CorNova Shares.  The aggregate shares of the
common stock of CorNova in an amount of three million (3,000,000) shares to be
issued to Cardiotech and Implant shall be referred to herein as the “CorNova
Shares” and will equal sixty percent (60%) of the issued and outstanding capital
stock of CorNova, on a fully diluted basis, including any shares underlying any
warrants or options, immediately prior to the issuance of any shares under the
Series A Financing.

 

ARTICLE V.     Exchange of Shares

 

5.1           Exchange of Shares.  The Contributory Shares, Investment Shares
and the CorNova Shares shall be issued in accordance with Articles I, III and IV
hereof, and shall be exchanged in accordance with this Article V (the
“Exchange”).

 

  (a)  The Contributory Shares shall be delivered in accordance with Article I,
and the Contributory Shares shall be deemed exchanged upon such event.  However
such shares shall be held by the Seed Loan lenders or by CorNova, as trustee for
such lenders as collateral subject to a security interest, and may not be
transferred or otherwise disposed of by CorNova prior to either the minimum
closing or the termination of the Series A Financing.

 

  (b)  The Investment Shares shall be delivered in accordance with Article III
and shall be deemed exchanged upon the minimum closing of the Series A
Financing.  However such shares shall be held by the Series A Financing
investors or by CorNova, as trustee for such investors as collateral subject to
a security interest, and may not be transferred or otherwise disposed of by
CorNova prior to satisfaction of the milestones set forth in §2.4(m) hereof.

 

  (c)  The CorNova Shares shall be delivered in accordance with Article IV and
shall be deemed exchanged upon receipt and exchange of the Contributory Shares.

 

  (d)  The consideration for the Exchange shall be the shares mutually delivered
and exchanged as herein set forth, and the license of the Technology as set
forth in Article VIII hereof.

 

ARTICLE VI.     Shares, and Limitations on Shares

 

6.1                                 Shares to be Fully Paid.  (a) CorNova
covenants that all shares of common stock which may be issued upon the Exchange
will be fully paid and nonassessable, and

 

8

--------------------------------------------------------------------------------

 

free of all liens and encumbrances.

 

  (b) Cardiotech covenants that all shares of common stock which may be issued
upon the Exchange will be fully paid and nonassessable, and free of all liens
and encumbrances.

 

  (c) Implant covenants that all shares of common stock which may be issued upon
the Exchange will be fully paid and nonassessable, and free of all liens and
encumbrances.

 

6.2           CorNova Limitation on Share Issuances.  CorNova covenants that
until either the minimum Series A Financing closing or the termination of the
Series A Financing, CorNova shall not:

 

(a) issue any securities, except:  (i) its initial capitalization of 2 million
shares which includes the 150,000 shares underlying those certain warrants
issued or to be issued in connection with the Seed Loans, (ii) the CorNova
Shares, and (iii) the shares to be issued under the Series A Financing.

 

(b) take any action which would cause any adjustments, recapitalizations,
splits, mergers, or other capital restructurings of its securities.

 

6.3           Reservation of Shares.  (a) CorNova has reserved, free from
preemptive rights, out of its authorized but unissued shares of common stock,
sufficient shares to provide for the issuance of the CorNova Shares.

 

  (b) Cardiotech has reserved, free from preemptive rights, out of its
authorized but unissued shares of common stock, sufficient shares to provide for
the issuance of the Cardiotech Investment Shares.

 

  (c) Implant has reserved, free from preemptive rights, out of its authorized
but unissued shares of common stock, sufficient shares to provide for the
issuance of the Implant Investment Shares.

 

ARTICLE VII.     Accredited Investors; Restricted Shares; Inside Information

 

7.1           Securities Laws Matters.

 

(a)  Investment Purpose.  CorNova recognizes and understands that the
Contributory Shares, and the Investment Shares, respectively, to be issued to
CorNova pursuant to this Agreement, and the Participants each recognize and
understand that the CorNova Shares to be issued to each of the Participants
pursuant to this Agreement, (collectively referred to as the “Securities”) for
investment and not with a view to the sale or distribution thereof, for its own
account and not on behalf of others (except its limited partners, or
shareholders) and has not granted any other person any right or option or any
participation or beneficial interest in any of the Securities.  CorNova and each
of the Participants confirms its understanding that the Securities constitute
restricted securities

 

9

--------------------------------------------------------------------------------

 

within the meaning of Rule 144 of the Commission under the Securities Act of
1933, as amended (the “Securities Act”), and that none of the Securities may be
sold except pursuant to an effective registration statement under the Securities
Act or under the securities laws of any state, or in a transaction exempt from
registration under the Securities Act, and acknowledges that it understands the
meaning and effect of such restriction.  CorNova and each of the Participants
are aware that no federal or state regulatory agency or authority has passed
upon the sale of the Securities or the terms of the sale or the accuracy or
adequacy of any material being provided to CorNova or to the Participants and
that the price of the Securities may not necessarily bear any relationship to
the underlying assets or value of the issuing company.  CorNova understands that
an investment in the Securities involves a degree of risk.  The Participants
each understand that an investment in the Securities involves a high degree of
risk.  The Securities are not being registered; neither the Participants nor
CorNova shall have any obligation or duty to register the Securities.  The
Securities will be issued in reliance upon exemptions from the Securities Act
and the securities laws which are predicated, in part, on the representations,
warranties and agreements of each of the Participants, and CorNova,
respectively, to the other, contained herein.

 

(b-1)  CorNova Qualifications.  CorNova represents and warrants that (i) CorNova
has business knowledge and experience, such experience being based on actual
participation therein of its chairman and its advisors, (ii) CorNova is capable
of evaluating the merits and risks of an investment in the Securities and the
suitability thereof as an investment therefor, (iii) the Securities to be
acquired by CorNova in connection with this Agreement will be acquired solely
for investment and not with a view toward resale or redistribution in violation
of the securities laws, and (iv) in connection with the transactions
contemplated hereby, no assurances have been made concerning the future results
of the Participants and their subsidiaries, if any, or as to the value of the
Securities.  CorNova understands that neither of the Participants or its
subsidiaries or affiliates is under any obligation to file a registration
statement or to take any other action under the securities laws with respect to
any such securities.

 

(b-2)  Participants Qualifications.  The Participants represent and warrant that
(i) the Participants have business knowledge and experience, such experience
being based on actual participation therein, (ii) the Participants are each
independently capable of evaluating the merits and risks of an investment in the
Securities and the suitability thereof as an investment therefor, (iii) the
Securities to be acquired by each of the Participants in connection with this
Agreement will be acquired solely for investment and not with a view toward
resale or redistribution in violation of the securities laws, (iv) in connection
with the transactions contemplated hereby, no assurances have been made
concerning the future results of CorNova or as to the value of the Securities
and (vi) each of the Participants are an “accredited investor” within the
meaning of Regulation D promulgated by the Securities and Exchange Commission
(the “Commission”) pursuant to the 1933 Act.  The Participants understand that
CorNova is closely-held and is not under any obligation to file a registration
statement or to take any other action under the securities laws with respect to
any such securities.

 

10

--------------------------------------------------------------------------------

 

(c)  Knowledge of Regulations.  The Participants, and CorNova had each consulted
with their own respective counsel in regard to the securities laws and are fully
aware (i) of the circumstances under which they are each required to hold the
Securities, (ii) of the limitations on the transfer or disposition of the
Securities, (iii) that the Securities must be held indefinitely unless the
transfer thereof is registered under the securities laws or an exemption from
registration is available and (iv) that no exemption from registration is likely
to become available for at least one year from the date of acquisition of the
Securities.  The Participants and CorNova have been advised by their respective
counsel as to the provisions of Rules 144 and 145 as promulgated by the
Commission under the 1933 Act and has been advised of the applicable limitations
thereof.  The Participants and CorNova each independently acknowledge that the
respective issuers of the Securities are relying upon the truth and accuracy of
the representations and warranties in this Article VII in consummating the
transactions contemplated by this Agreement and upon such reliance shall not be
registering the Securities under the securities laws.  The Participants each
independently acknowledge that CorNova is closely-held, and that no market
whatsoever exists with respect to any of CorNova’s securities and there are no
plans to develop a market.

 

(d-1)  Disclosures of Participants.  CorNova has been furnished with copies
through the Securities and Exchange Commission EDGAR website of:  (i) the
definitive proxy statements filed with the Commission in connection with the
annual meeting of stockholders of each of Cardiotech and Implant during the
previous 12 months, and (ii) copies of the Cardiotech and Implant Annual Reports
on Form 10-K for the fiscal year most recently ended, Cardiotech and Implant
Quarterly Reports on Form 10-Q for the quarter most recently ended, filed with
the Commission under the Exchange Act, and all Cardiotech and Current Reports on
Form 8-K filed during the previous 12 months, as filed with the Commission under
the Exchange Act (collectively, the “SEC Reports”).  The Participants have made
available to CorNova the opportunity to ask questions and receive answers
concerning the terms and conditions of the transactions contemplated by this
Agreement and to obtain any additional information which they possess or could
reasonably acquire for the purpose of verifying the accuracy of information
furnished to CorNova as set forth herein or for the purpose of considering the
transactions contemplated hereby.

 

(d-2)  Disclosures of CorNova.  The Participants has been furnished with a
summary description of the terms of the Securities and CorNova has made
available to the Participants the opportunity to ask questions and receive
answers concerning the terms and conditions of the transactions contemplated by
this Agreement and to obtain any additional information which they possess or
could reasonably acquire for the purpose of verifying the accuracy of
information furnished to the Participants as set forth herein or for the purpose
of considering the transactions contemplated hereby.

 

(e)  Opportunity to Meet with Management.  Management of CorNova, and management
of each of the Participants each acknowledge that it has had an opportunity

 

11

--------------------------------------------------------------------------------

 

to meet with and ask questions of the other’ as management concerning the
business and financial condition of the other, and the terms and conditions of
this transaction as well as to obtain such information as deemed necessary to be
requested.  Any questions or concerns raised concerning the transaction or the
other companies have been answered to the satisfaction of inquiring party.

 

(f)  Risk of Loss; Experience.  CorNova and each of the Participants respective
decision to engage in the Exchange is based upon its own independent evaluation
of the other.  Each party hereto recognizes that the Exchange is speculative. 
The parties have carefully reviewed and understands the various risks of the
Exchange, and CorNova and each of the Participants can afford to bear the risks
of engaging in the Exchange; including the risk of losing their respective
entire investment, and the risk that the Securities shall be illiquid for an
indefinite period of time.  CorNova and each of the Participants represent for
itself that it has the business and financial experience necessary to evaluate
the investment in the risks thereto.

 

(g)  Restrictive Legend.  The Participants and CorNova acknowledge and agree
that the certificates representing the Securities to be acquired pursuant to
this Agreement will be imprinted with a restrictive legend substantially as
follows:

 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER ANY APPLICABLE
STATE SECURITIES LAWS AND ARE “RESTRICTED SECURITIES” AS THAT TERM IS DEFINED IN
RULE 144 UNDER THE ACT.  NEITHER THE SHARES NOR ANY INTEREST THEREIN MAY BE
OFFERED FOR SALE, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED OF EXCEPT
PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE ACT AND SUCH STATE
SECURITIES LAWS OR AN EXEMPTION FROM REGISTRATION UNDER SUCH ACT AND SUCH LAWS
WHICH, IN THE OPINION OF COUNSEL FOR THE HOLDER, WHICH COUNSEL AND OPINION ARE
REASONABLY SATISFACTORY TO THE COUNSEL FOR THIS CORPORATION, IS AVAILABLE.

 

The Participants and CorNova understand and agree that appropriate stop transfer
notations will be placed in the records of the issuer and with its respective
transfer agent, if any, in respect of the Securities which are to be issued
pursuant to this Agreement.

 

7.2.          No Trading on Inside Information.  CorNova and the Participants
are hereby advised as follows:

 

The Participants are two publicly traded companies (collectively “P-T-Cs”).  The
use of material nonpublic information in securities transactions (referred to as
“Insider Trading”) or the communication of such information to others who use it
in securities trading (referred to as “Tipping”) violates the United States
federal securities laws.  Such violations may result in harsh consequences for
the individuals, entities or persons

 

12

--------------------------------------------------------------------------------

 

involved, including exposure to investigations by the U.S. Securities and
Exchange Commission (“SEC”), criminal and civil prosecution, disgorgement of any
profits realized or losses avoided (under certain laws and rules the calculation
of profits realized and losses avoided could exceed the actual amounts realized
or avoided) through the use of the nonpublic information and penalties based
upon such profits or losses.

 

The negotiations leading up to, and the signing of this Agreement, the Series A
Financing and the Closing contemplated hereunder, may constitute material
nonpublic information.  Accordingly, each person who reads this Agreement may be
prohibited by law from trading in the securities of the P-T-Cs or directly or
indirectly disclosing such information to any other person(s) so that they may
trade in the securities of the P-T-Cs, until two (2) full business days after
the respective P-T-Cs have made adequate public disclosure through a press
release or filed a report on Form 8-K with the SEC.

 

It is difficult to describe what constitutes “material” information, but each
person who reads this Agreement should assume that any information, positive or
negative, which might be of significance to an investor determining whether to
purchase, sell or hold the P-T-Cs’ securities, would be material.

 

7.3           No Disclosure until Closing of Series A Financing.  Until the
minimum closing of the Series A Financing has been consummated or terminated,
without the prior express written approval of all of the parties hereto, neither
CorNova nor either of the Participants shall make any public announcement with
respect to the Exchange or the Technology License, or any relationship between
the Participants and CorNova.  Notwithstanding however, that the Participants
shall not be prohibited from making public announcements or filings that are
required under any law or pursuant to the rules and regulations promulgated by
the Commission or the American Stock Exchange to which the Participants are
subject.  None of the parties hereto shall be prohibited from making any
disclosures with respect to the transactions and matters contemplated herein
under a subpoena or court order of competent jurisdiction.  Provided, however,
that the party required to make such disclosure, announcement or filing shall
immediately notify the other parties hereto of such pending disclosure to
provide them with an opportunity to object and intervene through appropriate
legal process.

 

ARTICLE VIII.     License of Technology & Venture

 

8.1           License of Technology.  Simultaneous with the issuance and
exchange of the Investment Shares, as set forth in Article III and the Exchange
as set forth in Article V, Cardiotech shall grant, convey and provide
(“Technology License”) to CorNova an exclusive license, subject to customary
terms and conditions to be set forth in a separate license agreement (the
“License”), for the technology consisting of Chronoflex DES polymer or any poly
(carbonate) urethane containing derivative thereof for use on drug-eluting
stents (collectively the “Technology”).

 

13

--------------------------------------------------------------------------------

 

8.2                                 No Collaboration.  Upon execution of this
Agreement and through the term of the License, Cardiotech shall not:  (a)
collaborate on or participate in any Technology research with other parties; or
(b) share, sell, transfer or otherwise provide any intellectual property with
respect to Technology research or products with other parties.

 

8.3                                 Venture.   CorNova shall focus its resources
on the development and marketing of innovative interventional cardiology
products.  The initial target of CorNova is the development of a next-generation
drug-eluting stent.  CorNova will direct its resources to develop or acquire
technology relating to stent design, CE testing and drug coatings, including but
not limited to Chronoflex DES polymer or any polycarbonate­polyurethane and
containing derivative thereof for use on drug-eluting stents.  Utilizing the
combined capabilities of the Participants, CorNova will seek to produce a novel
coronary stent system whose design, materials, and manufacturing will be
specific for drug elution technology.

 

ARTICLE IX.     Miscellaneous

 

9.1                                 Closing.  The closing of the Contributory
Shares and the CorNova Shares, and the subsequent completion of the Exchange of
the Investment Shares and the Technology License, provided for herein
(individually or collectively the “Closing”) shall occur the offices of one of
the Participants, or at such place and upon such date as CorNova and the
Participants may mutually agree.

 

9.2                                 Fees and Expenses.  Each party hereto shall
pay its own attorneys fees and its own out-of-pocket expenses incurred prior to
and in connection with the transactions contemplated hereby.  In addition,
CorNova shall pay the reasonable attorneys fees of the Participants’ counsel up
to an aggregate maximum of twenty thousand dollars ($20,000) in legal fees
including out-of-pocket expenses for their review and services in connection
with the Series A Financing.  CorNova shall, without incurring any further
expense, have a right to review or audit the legal fees and services provided
thereunder, and the right to review work product subject to redaction.

 

9.3                                 Modification, Termination or Waiver.  This
Agreement may be amended, modified, superseded or terminated, and any of the
terms, covenants, representations, warranties or conditions hereof may be
waived, but only by a written instrument executed by the party waiving
compliance.  The failure of any party at any time or times to require
performance of any provision hereof shall in no manner affect the right of such
party at a later time to enforce the same.

 

9.4                                 Notices.  Any notice requests, demands and
other communications required or which may be given hereunder shall be in
writing and shall be deemed to have been duly given if delivered either
personally or by either U.S. Mail certified or registered mail, postage prepaid,
or by overnight delivery service with all delivery charges prepaid, and fax if
available, addressed to the parties at their respective addresses

 

14

--------------------------------------------------------------------------------

 

set forth or referred to below:

 

If to CorNova, to:

With copies, to:

 

 

CorNova, Inc.

Kenneth B. Lerman, P.C.

274 Ash Street

651 Day Hill Road

Hopkinton, MA 01748

Windsor, Connecticut 06095

 

 

Attention:

S. Eric Ryan, M.D.

Attention: 

Kenneth B. Lerman, Esquire

 

Chairman

 

 

Fax: (508) 435-3866

Fax: (860) 285-0139

 

 

If to Cardiotech, to:

If to Cardiotech and/or Implant, with copies, to:

 

 

Cardiotech International, Inc.

 

78E Olympia Avenue

Attorneys at Law

Woburn, Massachusetts 01801

Ellenoff Grossman & Schole LLP

 

370 Lexington Avenue

 

New York, New York 10017

Attention:

Michael Szycher, Ph.D.,

Attention:  

Barry I. Grossman

 

Chairman & CEO

 

 

 

 

 

 

Fax: (781) 937-4218

Fax: (212) 370-7889

 

 

If to Implant, to:

 

 

 

Implant Sciences, Inc.

 

107 Audubon Road #5

 

Wakefield, Massachusetts 01880

 

 

 

Attention:

Anthony Armini, Ph.D.

 

 

President & CEO

 

Fax: (781) 246-1167

 

 

If mailed, delivery shall be deemed five (5) days after the date of mailing; if
overnight delivery, delivery shall be deemed the next business day provided such
services were selected and paid for.  The parties may change the persons and
addresses to which the notices or other communications are to be sent to it by
giving written notice of any such change in the manner provided herein for
giving notice.

 

9.5           Binding Effect and Assignment.

  This Agreement shall be binding upon and inure to the benefit of the
successors and assigns of the parties hereto.  No assignment of any rights or
delegation of any obligations provided for herein may be made by any party
without the express written consent of the other party.

 

15

--------------------------------------------------------------------------------

 

9.6                                 Entire Agreement.  This Agreement, along
with the other agreements referenced herein, contain the entire Agreement
between the parties with respect to the subject matter hereof.  In the event of
a conflict or inconsistency, this Agreement is the definitive and governing
agreement with respect to the subject matter hereof.

 

9.7                                 Calendar Days.  All references to “days” in
this agreement with respect to the amount of time allocated for notices,
performance or other periods shall mean calendar days, unless otherwise
specified.

 

9.8                                 Exhibits.  All Exhibits annexed hereto and
the documents and instruments referred to herein or required to be delivered
simultaneously herewith or at the Closing are expressly made a part of this
Agreement as fully as though completely set forth herein, and all references to
this Agreement herein or in any such Exhibits, documents or instruments shall be
deemed to refer to and include all such Exhibits, documents and instruments. 
Any execution of this Agreement is subject to the receipt of current and
complete exhibits.

 

9.9                                 Governing Law.  This Agreement shall be
governed by, and construed in accordance with the laws of the State of Delaware.

 

9.10                           Consent to Jurisdiction.  The parties here to
consent to jurisdiction of the Courts of the State of Massachusetts and to the
U.S. District Court in the District of Massachusetts.

 

9.11                           Counterparts.  This Agreement may be executed in
counterparts, each of which shall be deemed to be an original, but which
together shall constitute one and the same instrument.

 

9.12                           Section Headings.  The section headings contained
in this Agreement are inserted for convenience of reference only and shall not
affect the meaning or interpretation of this Agreement.

 

[The remainder of this page has been left intentionally blank.  The Signature
page follows.]

 

16

--------------------------------------------------------------------------------

 

WITNESS the execution of this Agreement as of the date first above written.

 

 

 

CorNova, Inc.

 

 

 

By:

  /s/ S. Eric Ryan

 

S. Eric Ryan

 

Chairman

 

 

 

 

Cardiotech International, Inc.

Implant Sciences, Inc.

 

 

By:

 /s/ Michael Szycher

 

By:

/s/ Anthony Armini

 

Michael Szycher

Anthony Armini

Chairman & CEO

President & CEO

 

17

--------------------------------------------------------------------------------